Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19
Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19
复制标题
DOI：
10.1002/ana.25987
复制
发表时间：
2020-12-28
影响因子：
11.2
通讯作者：
Gonzalez del Castillo, Juan
中科院分区：
文献类型：
--
作者：
Fragiel, Marcos;Miro, Oscar;Gonzalez del Castillo, Juan
在为期两个月的疫情高峰期间，我们在61家西班牙急诊室（ED）就诊的71，904名新冠肺炎患者中诊断出11例格林-巴利综合征（GBS）病例。艾德患者中GBS的相对频率在COVID中更高（千分之0.15）比非COVID（0.02份/千）患者（比值比[OR] = 6.30，95%置信区间[CI] = 3.18-12.5），标准化发生率也是如此。分别为9.44和0.69例/10万居民年，OR = 13.5，95% CI = 9.87-18.4。在临床特征方面，COVID-GBS患者的嗅觉-味觉障碍比非COVID-GBS患者（OR = 27.59，95%CI = 1.296-587）和COVID-非GBS患者（OR = 7.875，95%CI = 1.587-39.09）更常见。尽管COVID-GBS患者更频繁地被送进重症监护室，但与对照组相比，死亡率并没有增加。我们的研究结果表明SARS-CoV-2可能是另一种引起GBS的病毒感染。ANN NEUROL 2020
We diagnosed 11 Guillain-Barre syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15 parts per thousand) than non-COVID (0.02 parts per thousand) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2020